Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Background: Lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Valerio, Martinotti, Giovanni, De Berardis, Domenico, Maina, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737174/
https://www.ncbi.nlm.nih.gov/pubmed/36498129
http://dx.doi.org/10.3390/ijerph192316057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737174/
https://www.ncbi.nlm.nih.gov/pubmed/36498129
http://dx.doi.org/10.3390/ijerph192316057

Ejemplares similares